PMID- 29285020
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1611-2156 (Print)
IS  - 1611-2156 (Electronic)
IS  - 1611-2156 (Linking)
VI  - 16
DP  - 2017
TI  - The relationship between serum levels of fibroblast growth factor 21 and diabetic 
      retinopathy.
PG  - 1249-1256
LID - 10.17179/excli2017-672 [doi]
AB  - Fibroblast growth factor 21 (FGF21) is a major metabolic regulator that has been 
      shown to be elevated in a number of metabolic disturbances including type 2 
      diabetes mellitus (T2DM) and the metabolic syndrome, but few studies about the 
      relationship between serum FGF21 and the complications of diabetes have been 
      done. Since the association between FGF21 and diabetic retinopathy is not clear, 
      this study was conducted to investigate this relationship. In this 
      cross-sectional study, 61 subjects (14 healthy controls, 22 diabetic patients 
      without retinopathy, and 25 patients with diabetic retinopathy) were evaluated. 
      All patients in the study were examined for the presence of diabetic retinopathy. 
      Various clinical and biochemical parameters including FGF21 were evaluated and 
      analyzed and compared between the study groups. Serum levels of FGF21 showed a 
      significant difference between the three groups (P=0.003) but the difference 
      between diabetic patients with and without retinopathy was not significant 
      (P=0.122). Regression model was used to evaluate the role of FGF21 in predicting 
      diabetic retinopathy. In the multivariate logistic regression model after 
      adjustment of systolic blood pressure and fasting blood glucose, the level of 
      FGF21 was not associated with diabetic retinopathy. In the multivariate model, 
      only fasting blood glucose was associated with diabetic retinopathy (P=0.009). 
      According to the results of this study, serum levels of FGF21 in diabetic 
      patients was higher than the control group but these raised levels could not 
      predict the presence of diabetic retinopathy.
FAU - Mousavi, Zohre
AU  - Mousavi Z
AD  - Endocrine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Bonakdaran, Shokoufeh
AU  - Bonakdaran S
AD  - Endocrine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Sahebkar, Amirhossein
AU  - Sahebkar A
AD  - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad 
      University of Medical Sciences, Mashhad, Iran.
AD  - School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Yaghoubi, Gholamhossein
AU  - Yaghoubi G
AD  - Birjand University of Medical Science, Birjand, Iran.
FAU - Yaghoubi, Mohammad Ali
AU  - Yaghoubi MA
AD  - Endocrine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Davoudian, Najmeh
AU  - Davoudian N
AD  - Endocrine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Mohebbi, Masoud
AU  - Mohebbi M
AD  - Endocrine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
LA  - eng
PT  - Journal Article
DEP - 20171122
PL  - Germany
TA  - EXCLI J
JT  - EXCLI journal
JID - 101299402
PMC - PMC5735335
OTO - NOTNLM
OT  - diabetic retinopathy
OT  - fibroblast growth factor 21
OT  - type 2 diabetes mellitus
EDAT- 2017/12/30 06:00
MHDA- 2017/12/30 06:01
PMCR- 2017/11/22
CRDT- 2017/12/30 06:00
PHST- 2017/07/27 00:00 [received]
PHST- 2017/11/10 00:00 [accepted]
PHST- 2017/12/30 06:00 [entrez]
PHST- 2017/12/30 06:00 [pubmed]
PHST- 2017/12/30 06:01 [medline]
PHST- 2017/11/22 00:00 [pmc-release]
AID - 2017-672 [pii]
AID - Doc1249 [pii]
AID - 10.17179/excli2017-672 [doi]
PST - epublish
SO  - EXCLI J. 2017 Nov 22;16:1249-1256. doi: 10.17179/excli2017-672. eCollection 2017.